Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01358357
Registration number
NCT01358357
Ethics application status
Date submitted
19/05/2011
Date registered
23/05/2011
Date last updated
7/09/2016
Titles & IDs
Public title
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder
Query!
Secondary ID [1]
0
0
2011-000986-10
Query!
Secondary ID [2]
0
0
D1050296
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PERSIST
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bipolar I Disorder
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lurasidone
Treatment: Drugs - Placebo
Experimental: Lurasidone 20-80 mg flexible dose -
Placebo Comparator: Placebo -
Treatment: Drugs: Lurasidone
Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
Treatment: Drugs: Placebo
20-80 mg flexible dose
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to Recurrence of Mood Event During the Double Blind Treatment Phase
Query!
Assessment method [1]
0
0
A mood event is defined as one of the following during the double-blind phase:
(1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyond dosage allowed for anxiety, agitation, or insomnia). (3) Psychiatric hospitalization for any bipolar mood episode. (4) Young Mania Rating Scale (YMRS) or Montgomery-Asberg Depression Rating Scale (MADRS) total score = 18 or Clinical Global Impression Bipolar Version, Severity of Illness (CGI BP S) score = 4 at 2 consecutive assessments no more than 10 days apart. (5) Discontinuation from the study because of a mood event (as determined by the Investigator).
Query!
Timepoint [1]
0
0
28 weeks (up to 33 weeks)
Query!
Secondary outcome [1]
0
0
Time to All-cause Discontinuation
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
28 weeks (up to 33 weeks)
Query!
Secondary outcome [2]
0
0
Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
28 weeks (up to 33 weeks)
Query!
Secondary outcome [3]
0
0
Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
28 weeks
Query!
Secondary outcome [4]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score
Query!
Assessment method [4]
0
0
The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1=Normal, not at all ill, to 7=Among the most extremely ill patients. a higher score is associated with greater illness severity.
Query!
Timepoint [4]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [5]
0
0
Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score
Query!
Assessment method [5]
0
0
The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A high score is associated with greater illness severity
Query!
Timepoint [5]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [6]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score
Query!
Assessment method [6]
0
0
The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with a greater illness severity.
Query!
Timepoint [6]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [7]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score
Query!
Assessment method [7]
0
0
the YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of maia.
Query!
Timepoint [7]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [8]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score
Query!
Assessment method [8]
0
0
The MADRS consists of 10 items, each rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depressive symptoms.
Query!
Timepoint [8]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [9]
0
0
Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score
Query!
Assessment method [9]
0
0
The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.
Query!
Timepoint [9]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [10]
0
0
Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score
Query!
Assessment method [10]
0
0
The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Query!
Timepoint [10]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [11]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score
Query!
Assessment method [11]
0
0
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.
Query!
Timepoint [11]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [12]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score
Query!
Assessment method [12]
0
0
The PIRS-2 is a 2-item self-report of insomnia assessed via a computer interface. Each item is scored from 0-3. The PIRS-2 total score is calculated as the sum of the 2 items. The PIRS total score ranges from 0 to 6. Higher scores are associated with greater severity of insomnia.
Query!
Timepoint [12]
0
0
Double-blind Baseline to week 28
Query!
Secondary outcome [13]
0
0
Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score
Query!
Assessment method [13]
0
0
The Q-LES-Q-SF is a 16-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living. The questionnaire was developed and validated for use in depressed outpatient subjects and has eight summary scales that reflect major areas of functioning: physical health, mood, leisure time activities, social relationships, general activities, work, household duties and school/coursework. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The Q-LES-Q-SF percentage maximum possible score is calculated as 100 × (Raw Score - 14 [Minimum Score]) / (70 [Maximum Score] - 14 [Minimum Score]). Higher percent maximum scores indicate better quality of life.
Query!
Timepoint [13]
0
0
Double-blind Baseline to week 28
Query!
Eligibility
Key inclusion criteria
Open-label Phase
- 18 years of age or older
- Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision
(DSM-IV-TR) diagnosis of bipolar I disorder
•= 1 manic, mixed manic, or depressed episode in past 2 years
- YMRS or MADRS total score = 14 if on lithium or divalproex; = 18 if not on lithium or
divalproex
Double-blind Phase
- Subjects must achieve consistent clinical stability, defined as total scores = 12 on
the YMRS and MADRS over at least 12 weeks, with the allowance of two excursions (YMRS
and/or MADRS total scores up to 13 or 14, respectively) except during the last 4 weeks
before randomization
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Open Label Phase
- Diagnosis of an Axis I or Axis II disorder, other than bipolar I disorder, that is the
primary focus of treatment within 3 months of screening
- Subjects for whom diagnostic agreement between the Investigator and United BioSource
Corporation (Boston) (UBC) cannot be reached
- Ultra-fast rapid cycling (defined as = 8 mood episodes over the previous 12-month
period)
- Subjects who test positive for drugs of abuse at screening. In the event a subject
tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate
the subject's ability to abstain from cannabis during the study
- Unstable/inadequately treated medical illness
- The subjects answers "yes" to "Suicidal Ideation" items 4 or 5 on the C-SSRS (at time
of evaluation)
Double Blind Phase
- Subjects who in the Investigator's judgment have not been compliant with study
medication during the stabilization phase
- Subjects who have not stabilized during the open-label phase (within 20 weeks)
- Subjects who test positive for drugs of abuse at double-blind phase baseline. In the
event a subject tests positive for cannabinoids (tetrahydrocannabinol), the
Investigator will evaluate the subject's ability to abstain from cannabis during the
study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
965
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
The Lyell McEwin Hospital - Elizabeth Vale
Query!
Recruitment hospital [2]
0
0
RWF Medic Pty Ltd as Trustee for Farnbach Family Trust at Neurotherapy Victoria - Malvern
Query!
Recruitment hospital [3]
0
0
The Melbourne Clinic - Richmond
Query!
Recruitment hospital [4]
0
0
Hollywood Medical Centre - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [2]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [3]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [4]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oklahoma
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Rhode Island
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Provincia de Cordoba
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Santa Fe
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Buenos Aires
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Cordoba
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
La Plata
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Mendoza
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Bourgas
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Plovdiv
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Rousse
Query!
Country [25]
0
0
Bulgaria
Query!
State/province [25]
0
0
Sofia
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Varna
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Santiago
Query!
Country [28]
0
0
Croatia
Query!
State/province [28]
0
0
Rijeka
Query!
Country [29]
0
0
Croatia
Query!
State/province [29]
0
0
Zagreb
Query!
Country [30]
0
0
Croatia
Query!
State/province [30]
0
0
Zagreg
Query!
Country [31]
0
0
Czech Republic
Query!
State/province [31]
0
0
Brno-Bohunice
Query!
Country [32]
0
0
Czech Republic
Query!
State/province [32]
0
0
Brno
Query!
Country [33]
0
0
Czech Republic
Query!
State/province [33]
0
0
Havirov
Query!
Country [34]
0
0
Czech Republic
Query!
State/province [34]
0
0
Pisek
Query!
Country [35]
0
0
Czech Republic
Query!
State/province [35]
0
0
Prague 8-Bohunice
Query!
Country [36]
0
0
Czech Republic
Query!
State/province [36]
0
0
Prague
Query!
Country [37]
0
0
Czech Republic
Query!
State/province [37]
0
0
Praha 10
Query!
Country [38]
0
0
Czech Republic
Query!
State/province [38]
0
0
Praha 3
Query!
Country [39]
0
0
Czech Republic
Query!
State/province [39]
0
0
Praha 4
Query!
Country [40]
0
0
Czech Republic
Query!
State/province [40]
0
0
Prerov
Query!
Country [41]
0
0
Czech Republic
Query!
State/province [41]
0
0
Usti nad labem
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Dijon cedex
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Dole
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Montpellier Cedex 5
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Nimes Cedex 09
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Budapest
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Gyor
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Gyula
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Gunma
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Hokkaido
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Nagano
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Osaka
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Saga
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Tokyo
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Aichi
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Hachioji, Tokyo
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Kumamoto
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Okinawa
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Toyama
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Gdynia
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Kielce
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Torun
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Tuszyn
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Wroclaw
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Izhevsk
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Nizhniy Novgorod
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
St. Petersburg
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Tomsk
Query!
Country [69]
0
0
Serbia
Query!
State/province [69]
0
0
Belgrade
Query!
Country [70]
0
0
Serbia
Query!
State/province [70]
0
0
Kragujevac
Query!
Country [71]
0
0
Serbia
Query!
State/province [71]
0
0
Nis
Query!
Country [72]
0
0
Serbia
Query!
State/province [72]
0
0
Novi Knezevac
Query!
Country [73]
0
0
Slovakia
Query!
State/province [73]
0
0
Rimavska Sobota
Query!
Country [74]
0
0
Slovakia
Query!
State/province [74]
0
0
Zlate Moravce
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sumitomo Pharma America, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study
designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or
divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without
rapid cycling and /or psychotic features.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01358357
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director, MD
Query!
Address
0
0
Sumitomo Pharma America, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01358357
Download to PDF